The Electron Microscopy Shared Resource (EMSR) is an institutional research resource laboratory providing specimen preparation, microscopy and digital imaging services to investigators within the Mayo Clinic. Centrally located in the Guggenheim Research Building on the 14th floor on the Rochester Campus, the shared resource is fully equipped to offer standard transmission (TEM) and scanning (SEM) electron microscopy. The shared resource also performs X-ray probe microanalysis, electron tomography, cryoultramicrotomy, and immuno-gold labeling procedures. Costs are recovered primarily through recharges to investigator budgets and through institutional support. The facility has been an important shared resource of the Mayo Clinic Cancer Center (MCCC) since 2004. The requested budget will support, in part, current EMSR services utilized by cancer center members, and partially offset the resource's projected yearly operational expenditures of $1,202,039. Usage of the EMSR by MCCC members account for an average utilization of -20% of the EMSR's services and operations during the period from 2003 to 2007. The budget requested for the next five year period will support 8% of the resource's expenses and operations provided to MCCC members. The EMSR provides additional value to Mayo Clinic Cancer Center members in three ways: First the EMSR is continuously developing and implementing new techniques and procedures in electron microscopy directed specifically to the individual needs of MCCC Members. New methods under development include electron tomography, cryo ultramicroscopy, 3-D image analysis, electron diffraction and microwave processing. Second, MCCC member projects are given first priority in the laboratory's specimen handling queue. And finally, MCCC member projects are directly subsidized through discounts.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications